CN112739683A - 布瓦西坦的制备方法及其中间体 - Google Patents

布瓦西坦的制备方法及其中间体 Download PDF

Info

Publication number
CN112739683A
CN112739683A CN201980059753.0A CN201980059753A CN112739683A CN 112739683 A CN112739683 A CN 112739683A CN 201980059753 A CN201980059753 A CN 201980059753A CN 112739683 A CN112739683 A CN 112739683A
Authority
CN
China
Prior art keywords
formula
compound
acid
preparation
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980059753.0A
Other languages
English (en)
Other versions
CN112739683B (zh
Inventor
郭朋
刘凤伟
任建笑
朱文峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bopunuo Shanghai Pharmaceutical Technology Development Co ltd
Shanghai Xuantai Pharmaceutical Technology Co ltd
Original Assignee
Shanghai Vastpro Technology Development Co ltd
Shanghai Xuantai Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Vastpro Technology Development Co ltd, Shanghai Xuantai Pharmaceutical Technology Co Ltd filed Critical Shanghai Vastpro Technology Development Co ltd
Publication of CN112739683A publication Critical patent/CN112739683A/zh
Application granted granted Critical
Publication of CN112739683B publication Critical patent/CN112739683B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种布瓦西坦的制备方法、其中间体以及中间体的制备方法。该方法原料结构简单，价格低廉且易于获得。所有步骤反应条件温和，操作简单，无低温或严格无水无氧条件要求，无特殊分离手段，适合工业化生产。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN201980059753.0A 2018-09-12 2019-09-10 布瓦西坦的制备方法及其中间体 Active CN112739683B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2018/105203 WO2020051796A1 (zh) 2018-09-12 2018-09-12 布瓦西坦的制备方法及其中间体
CNPCT/CN2018/105203 2018-09-12
PCT/CN2019/105111 WO2020052545A1 (zh) 2018-09-12 2019-09-10 布瓦西坦的制备方法及其中间体

Publications (2)

Publication Number Publication Date
CN112739683A true CN112739683A (zh) 2021-04-30
CN112739683B CN112739683B (zh) 2024-04-16

Family

ID=69776959

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980059753.0A Active CN112739683B (zh) 2018-09-12 2019-09-10 布瓦西坦的制备方法及其中间体

Country Status (2)

Country Link
CN (1) CN112739683B (zh)
WO (2) WO2020051796A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112939900B (zh) * 2019-12-10 2024-01-16 广东东阳光药业股份有限公司 一种布瓦西坦中间体的制备方法
CN113582902A (zh) * 2020-04-30 2021-11-02 浙江华海药业股份有限公司 布瓦西坦及其中间体的制备方法
CN112143764B (zh) * 2020-09-24 2022-04-19 奥锐特药业股份有限公司 一种生物酶催化制备布瓦西坦中间体化合物的方法
US11384050B1 (en) * 2021-02-03 2022-07-12 Vitaworks Ip, Llc Method for preparing levetiracetam and intermediates thereof
CN113559318B (zh) * 2021-07-05 2022-09-13 四川大学 一种促神经功能恢复的手性导电修复支架及其制备方法
US11884623B2 (en) * 2022-05-23 2024-01-30 Divi's Laboratories Ltd. Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam
CN114989061A (zh) * 2022-08-03 2022-09-02 江苏同禾药业有限公司 一种布瓦西坦的制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101448779A (zh) * 2006-05-24 2009-06-03 特瓦制药工业有限公司 R-(+)-3-(氨基甲酰甲基)-5-甲基己酸及其盐的制备方法
WO2016075082A1 (en) * 2014-11-10 2016-05-19 Sandoz Ag Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam
CN106432030A (zh) * 2015-10-10 2017-02-22 苏州鹏旭医药科技有限公司 布瓦西坦的一种制备方法
WO2017076737A1 (en) * 2015-11-03 2017-05-11 Ucb Biopharma Sprl Continuous process for preparing brivaracetam
CN107216276A (zh) * 2017-06-29 2017-09-29 爱斯特（成都）生物制药股份有限公司 一种新的布瓦西坦的合成方法
WO2018042393A1 (en) * 2016-09-05 2018-03-08 Micro Labs Limited Novel process for the preparation of brivaracetam
CN108503573A (zh) * 2017-02-24 2018-09-07 北京艾百诺医药股份有限公司 一种布瓦西坦的新的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338621B2 (en) * 2005-12-21 2012-12-25 Ucb S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
KR20080027880A (ko) * 2006-05-24 2008-03-28 테바 파마슈티컬 인더스트리즈 리미티드 Ｒ-(+)-3-(카바모일메틸)-5-메틸헥산산 및 이의 염의 제조방법

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101448779A (zh) * 2006-05-24 2009-06-03 特瓦制药工业有限公司 R-(+)-3-(氨基甲酰甲基)-5-甲基己酸及其盐的制备方法
WO2016075082A1 (en) * 2014-11-10 2016-05-19 Sandoz Ag Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam
CN106432030A (zh) * 2015-10-10 2017-02-22 苏州鹏旭医药科技有限公司 布瓦西坦的一种制备方法
WO2017076737A1 (en) * 2015-11-03 2017-05-11 Ucb Biopharma Sprl Continuous process for preparing brivaracetam
WO2018042393A1 (en) * 2016-09-05 2018-03-08 Micro Labs Limited Novel process for the preparation of brivaracetam
CN108503573A (zh) * 2017-02-24 2018-09-07 北京艾百诺医药股份有限公司 一种布瓦西坦的新的制备方法
CN107216276A (zh) * 2017-06-29 2017-09-29 爱斯特（成都）生物制药股份有限公司 一种新的布瓦西坦的合成方法

Also Published As

Publication number Publication date
WO2020052545A1 (zh) 2020-03-19
CN112739683B (zh) 2024-04-16
WO2020051796A1 (zh) 2020-03-19

Similar Documents

Publication Publication Date Title
CN112739683A (zh) 布瓦西坦的制备方法及其中间体
CN109516943B (zh) 一种高手性纯度内酰胺中间体及布瓦西坦的制备方法
AU2010209686B2 (en) Method for synthesis of (1S, 2R)-milnacipran
CZ384697A3 (cs) Způsob přípravy kyseliny (S)-3-(aminomethyl)-5-methylhexanové
EP2914574B1 (en) New process
AU2011222644A1 (en) Improved resolution methods for isolating desired enantiomers of tapentadol intermediates and use thereof for the preparation of tapentadol
CN113024396A (zh) 一种奥司他韦的制备方法及其中间体
HUE031138T2 (en) A method of producing lacosamide
US5516943A (en) Process for preparing cyclic CIS-1-amino-2-alkanols
CN113024434A (zh) 一种布瓦西坦中间体的制备方法
CN112920053B (zh) 一种手性α-甲基芳乙胺的制备方法
EP1464638A1 (en) Process for producing erythro-3-amino-2-hydroxybutyric acid derivatives
WO2007080470A2 (en) A method for the purification of levetiracetam
CN109265385B (zh) 一种手性催化剂的合成工艺
EP2399901A1 (en) Intermediate for producing lacosamide and a process for its preparation and conversion to lacosamide
CN108203396B (zh) 一种脑啡肽酶抑制剂的合成
JP3088328B2 (ja) 光学活性２−フェニル−２−（２’−ピペリジニル） 酢酸エステル誘導体の製造方法
CN110981934A (zh) 一种阿加曲班水合物的合成方法
US5380849A (en) Process for optically pure decahydroisoqiunolines
CN115490626B (zh) 一种pf-07321332的关键手性化合物及其制备方法
AU7870894A (en) Process for preparing cyclic cis-1-amino-2-alkanols
CN114195684B (zh) 一种氨基保护基n-取代手性氨基酸的合成方法
JP5704763B2 (ja) トランス−４−アミノシクロペンタ−２−エン−１−カルボン酸誘導体の製造
CN106866453A (zh) 一种微反应器制备拉科酰胺的方法
JPS6383056A (ja) ジアステレオマーの分割

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240905

Address after: Room 205 and 207, 515 huanke Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201210

Patentee after: Shanghai xuantai Pharmaceutical Technology Co.,Ltd.

Country or region after: China

Patentee after: Bopunuo (Shanghai) Pharmaceutical Technology Development Co.,Ltd.

Address before: Room 205 and 207, 515 huanke Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201210

Patentee before: Shanghai xuantai Pharmaceutical Technology Co.,Ltd.

Country or region before: China

Patentee before: SHANGHAI VASTPRO TECHNOLOGY DEVELOPMENT Co.,Ltd.